EGFR and non-small cell lung carcinoma: With advances in targeted therapies, molecularly targeted agents that inhibit epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) can significantly improve the efficacy and reduce the toxicity of NSCLC, as almost all these gene mutations are found in ADC [6, 7].